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Abstract 
BACKGROUND: Hypoxia within acute venous thrombi is thought to drive 
resolution through stabilisation of hypoxia inducible factor 1 alpha (HIF1α). 
Prolyl hydroxylase domain (PHD) isoforms are critical regulators of HIF1α 
stability. Non-selective inhibition of PHD isoforms with l-mimosine has been 
shown to increase HIF1α stabilisation and promote thrombus resolution. 
OBJECTIVE: The aim of this study was to investigate the therapeutic potential 
of PHD inhibition in venous thrombus resolution.  
METHODS: Thrombosis was induced in the inferior vena cava of mice using a 
combination of flow restriction and endothelial activation. Gene and protein 
expression of PHD isoforms in the resolving thrombus was measured by RT-
PCR and immunohistochemistry. Thrombus resolution was quantified in mice 
treated with pan PHD inhibitors AKB-4924 and JNJ-42041935 or inducible all-
cell Phd2 knockouts by micro-computed tomography, 3D high frequency 
ultrasound or endpoint histology. 
RESULTS: Resolving venous thrombi demonstrated significant temporal gene 
expression profiles for PHD2 and PHD3 (P<0.05), but not for PHD1. PHD 
isoform protein expression was localised to early and late inflammatory cell 
infiltrates. Treatment with selective pan PHD inhibitors, AKB-4924 and JNJ-
42041935, enhanced thrombus neovascularisation (P<0.05), but had no 
significant effect on overall thrombus resolution. Thrombus resolution or its 
markers, macrophage accumulation and neovascularisation, did not differ 
significantly in inducible all-cell homozygous Phd2 knockouts compared with 
littermate controls (P>0.05).  
CONCLUSIONS: This data suggests that PHD-mediated thrombus 
neovascularisation has a limited role in the resolution of venous thrombi. 
Directly targeting angiogenesis alone may not be a viable therapeutic strategy 
to enhance venous thrombus resolution. 
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Introduction 
Deep vein thrombosis (DVT) is a common condition with an annual incidence 
of roughly 1 in 1000 in the general population 1. Common complications 
include pulmonary embolism and post-thrombotic syndrome (PTS) that are 
significant sources of mortality and morbidity respectively 2. Clinical studies 
show that rapid clearance of thrombus, by thrombolysis or faster natural 
resolution, is associated with a reduced incidence of PTS 3, 4. While effective 
in preventing recurrence standard anticoagulant therapies do not aid in 
clearance of the initial thrombotic insult. Novel treatments that aim to enhance 
natural venous thrombus resolution may, therefore, be of value in reducing 
the burden of PTS in patients with DVT. 
 
The early venous thrombus is acutely hypoxic resulting in nuclear 
accumulation of HIF1α in thrombus resident cells 5. Enhanced stabilisation of 
HIF1α in the thrombus following treatment with l-mimosine significantly 
enhanced thrombus resolution, accompanied by increased macrophage 
recruitment, neovascular channel formation and the production of vascular 
endothelial growth factor A (VEGF-A) 5. Expression of HIF1α and the 
transcriptional target VEGF-A are also increased in the thrombosed vessel 
wall 6. In contrast to l-mimosine adenoviral overexpression of HIF1α in the 
thrombus failed to significantly enhance thrombus resolution despite resulting 
in a doubling of active HIF1α 7. HIF2α is also expressed in the resolving 
venous thrombus primarily in macrophage rich regions, however, the 
contribution of this isoform to thrombus resolution has yet to be determined 8.   
 
The biological effect of l-mimosine has been attributed to the capacity of this 
agent to inhibit the prolyl hydroxylase domain (PHD) containing proteins. 
However, it is important to note that as a potent metal ion chelator this agent 
may also inhibit the activity of related enzymes including the collagen prolyl 4-
hydroxylases 9-11. In a recent study Kiriakidis and colleagues demonstrated 
that l-mimosine inhibited the collagen prolyl-4-hydroxylase dependent release 
of complement C1q by macrophages 12. 
 
PHD proteins serve as critical molecular oxygen sensors through regulation of 
HIFα subunit stability. Under-normoxic conditions PHD isoforms hydroxylate 
HIFα subunits in an oxygen and 2-oxoglutarate dependent manner leading to 
ubiquitination and subsequent proteasomal degradation. Under hypoxic 
conditions in which oxygen is rate-limiting PHD isoforms are inactivated 
allowing HIFα subunits to translocate to the nucleus and form transcriptionally 
active complexes 13. HIF1α transcriptional targets include a number of genes 
implicated in thrombus resolution including VEGF-A, plasminogen activator 
inhibitor 1 and inducible nitric oxide synthase14. 
 
Recently a number of novel PHD inhibitors have been developed, which are 
reported to offer improved specificity15, 16. The capacity of this new generation 
of PHD inhibitors to modulate venous thrombus resolution has yet to be 
determined. In parallel, the capacity of individual PHD isoforms to regulate 
cellular responses to tissue hypoxia has been extensively studied using 
isoform specific knockout mice. Importantly, these studies have strongly 
implicated loss of PHD2 with enhanced macrophage recruitment and 
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angiogenesis, processes implicated in the resolution of venous thrombi 17-19. 
However, the role of PHD2 in venous thrombus resolution has yet to be 
determined. 
 
The aim of this study was to determine the expression and distribution of PHD 
isoforms in the resolving thrombus. The role of PHD isoforms in thrombus 
resolution was investigated using the PHD inhibitors AKB-4924 and JNJ-
42041935. To complement the small molecule inhibitor strategy thrombus 
resolution was also characterised in inducible all-cell Phd2 knockouts.  
 
Methods 
 
PHD2 Knockouts 
For studies of inducible Phd2 deletion Phd2fl/fl; Rosa26creERT2/+ mice were 
crossed with Phd2fl/+ to obtain mice with the following genotypes (effective 
genotype in parentheses): Phd2fl/fl (Phd2+/+), Phd2fl/+ (Phd2+/+), 
Phd2fl/+;R26creERT2/+ (Phd2+/-) and Phd2fl/fl;R26creERT2/+ (Phd2-/-) as 
previously described 20. Conditional gene deletion was induced by 
intraperitoneal injection of Tamoxifen (Sigma, USA) at a dose of 
1mg/mouse/day, for 5 days prior to thrombus induction 20. Demographics of 
knockout mice and data of thrombus formation efficiency can be found in the 
data supplement (Supplementary Tables S1). 
 
Model of venous thrombosis 
All experimental animal procedures were carried out in accordance with the 
Animal (Scientific Procedures) Act 1986 (King’s College London, UK) or 
approved by the Institutional Animal Care and Research Advisory Committee 
(K.U. Leuven, Belgium). For inducible Phd2 knockout studies 6-12 week-old 
male and female mice on a C57BL/6J background were used. For natural 
thrombus resolution and PHD inhibitor studies 8-10 week old male BALB/c 
mice were used. Thrombus was induced using the St Thomas’ model of 
inferior vena cava thrombosis as previously described 21, 22. Mice 6-12 weeks 
in age were anaesthetised by isoflurane inhalation (3%, 1L/Min O2). A midline 
laparotomy was made, the bowel externalised and blunt dissection used to 
reveal the retroperitoneal structures. Using sharp dissection the IVC was 
separated from the aorta immediately distal to the left renal vein. A piece of 4-
0 Mersilk (Ethicon, USA) suture material was passed behind the IVC and tied 
onto a length of 5-0 prolene (Ethicon, UK) placed along the vessel. The 
prolene was removed resulting in an approximate 90% stenosis of the vessel. 
A mini bulldog serrefine vascular clamp (Fine Scientific Tools, Germany) was 
applied to the IVC at two locations distal to the site of stenosis for 20 seconds. 
Perioperative buprenorphine was administered by intraperitoneal injection at a 
dose of 0.1mg/kg. The bowel was internalised and layered closure of the 
abdomen achieved with continuous 4-0 polydiaxanone sutures (Ethicon, 
USA). Induction of thrombus in knockout mice was conducted in an operator-
blinded manner. 
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Drug Dosing 
AKB-4924 (kindly provided by Dr Robert Shalwitz, Akebia Therapeutics, USA) 
was provided at a concentration of 2mg/ml in 40% (v/v) aqueous 2-
hydroxypropyl-beta cyclodextrin, 60% (v/v) 50mM citrate buffer pH5. 8-10 
week old male BALB/c mice were randomised to receive either AKB-4924 at a 
dose of 5mg/kg or 10mg/kg, or vehicle control by daily subcutaneous injection 
starting 24hrs after thrombus induction, based on previous reports in the 
literature demonstrating doses in this range stabilized HIF1α and reduced 
disease severity in a model of colitis 15, 23, 24. JNJ-42041935 (kindly provided 
by Michael Rabinowitz, Johnson and Johnson, USA) was prepared in 20% 
(v/v) 2-hydroxypropyl-beta cyclodextrin at a concentration of 3mg/ml. 8-10 
week old male BALB/c mice were randomised to receive either JNJ-42041935 
at a dose of 35mg/kg or vehicle control by daily intraperitoneal injection 
starting 24 hours after thrombus induction based on previous reports in the 
literature demonstrating this dose is sufficient to induce HIF1α mediated 
erythropoietin expression and increase haemotocrit 16, 25, 26. 
 
Imaging of thrombus resolution 
Histology  IVC containing thrombus was excised, fixed overnight in 
10% (v/v) formal saline and processed for paraffin embedding. Transverse 
sections (5μm) were cut at 500μm intervals though the sample generating a 
series of levels over the entire length of the thrombus. Brightfield images of 
haematoxylin and eosin stained thrombus were captured and measurement of 
thrombus cross sectional area obtained (Image Pro Plus software, Media 
Cybernetics, UK) to enable analysis of thrombus volume and vein lumen 
recanalisation as previously described 5, 21. 
 
Contrast-enhanced microCT  Thrombus was imaged by contrast-
enhanced microCT as previously described 27. Images were reconstructed 
using VivoQuant software (v1.22, Invicro, USA) at a voxel size of 65μm. 
Reconstructed scans were segmented and analysed using ITKsnap software 
(Open Source) by a blinded observer to provide measurements of thrombus 
volume (see supplemental methods). 
 
3D high frequency ultrasound Thrombus was visualised by 3D HFUS 
using a Vevo2100 imaging unit with a 40MHz ultrasound probe attached to a 
stepper motor (Visual Sonics, Canada). A more detailed description is 
provided in the supplementary methods. Images were exported as DICOM 
files and thrombus segmented using Osirix software (v5.5, Open Source) by a 
blinded observer to provide measurements of thrombus volume (see 
supplemental methods) 28. 
 
Expression and localisation of PHDs 
Thrombus qPCR  Thrombi formed in 8-10 week old male Balb/c mice 
were separated from the surrounding IVC, immersed in RNAlater (Thermo 
Fisher), snap frozen in liquid nitrogen and stored at -80°C. Total RNA (mRNA) 
was extracted using Trizol (Thermo Fisher) and the RNeasy mini kit (Qiagen, 
Germany). RNA was reverse transcribed using the high-capacity RNA-to-
cDNA kit (Applied Biosystems, USA) and cDNA for phds1-3 quantified. 
Expression of PHD isoforms was normalised against housekeeping genes, 
Actb and Gak (see supplemental methods). 
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Immunohistochemistry (IHC)  Expression of PHD1, PHD2 and 
PHD3 was localised in the naturally resolving venous thrombus by IHC. After 
inhibition or deletion of PHD2 thrombus resident Mac2 positive macrophages 
and CD31 positive endothelial channels were localised by IHC. Further details 
of antigen retrieval, primary antibodies, signal amplification and subsequent 
analysis are provided in the supplemental methods. Images were obtained at 
50x and 200x with a light microscope (DMRB, Leica, Germany) using a digital 
camera (Micropublisher 3.3, QImaging, Canada). Stained sections were 
compared to appropriate IgG control to ensure specificity. Measurements of 
staining were obtained using Image Pro Plus software (Media Cybernetics, 
UK). 
 
Haematocrit measurements 
Blood was drawn under terminal anaesthesia by cardiocentesis into 
graduated EDTA anti-coagulated tubes (Greiner Bio-One, UK), centrifuged for 
10mins at 10,0000xg with measures of total volume of blood collected and 
mean corpuscular volume used to estimate haematocrit. 
 
Statistics 
Normality of data was assessed using D’Agostino and Pearson omnibus tests 
with parametric and non-parametric statistics selected as appropriate. Details 
of statistical tests used for individual datasets are provided in the 
accompanying figure legends. Data are represented as mean ± standard error 
(SE). Results were analysed using Prism software (v5, GraphPad, USA) with 
P<0.05 considered significant. 
 
Results 
 
Expression of PHD isoforms during natural thrombus resolution 
Expression of Phd1, 2 and 3 genes was detected at days 1, 3, 7 and 11 post-
induction by qPCR. While expression of Phd1 did not significantly change 
over time (P>0.05, Fig 1a), expression of Phd2 and Phd3 was found to 
change significantly over the timecourse of thrombus resolution studied 
(P<0.05, Fig 1b-c). Localisation of PHD1, 2 and 3 protein by 
immunohistochemistry revealed expression in the acute venous thrombus that 
may be attributed to the polymorphonuclear infiltrate whilst expression in the 
chronic thrombus is most likely associated with mononuclear cells that 
predominate at later time-points (Fig 1d).  
 
Effect of pan PHD inhibition, using AKB-4924 and JNJ-42041935 PHD 
inhibitors, on venous thrombus resolution 
Thrombus resolution was measured by longitudinal contrast-enhanced 
microCT at days 1, 7 and 14 post-induction in mice treated with the PHD 
inhibitor AKB-4924. There was no significant effect on temporal changes in 
thrombus size or rate of resolution following treatment with either 5 or 
10mg/kg AKB-4924 (P>0.05, Fig 2a-c). Similarly, endpoint histological 
measurements of thrombus volume and vein lumen recanalisation did not 
differ significantly after AKB-4924 treatment (P>0.05, Fig 2d-e). A dose 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 7 
dependent increase in thrombus macrophage content was observed at day 
14, but this was not significant (P>0.05, Fig 2f). However, treatment with AKB-
4924 was associated with a significant increase in thrombus 
neovascularisation (P<0.001, Fig 2g) attributed to the 10mg/kg treatment 
group (P<0.05).  
In mice treated with the PHD inhibitor JNJ-42041935 thrombus resolution was 
quantified by end-point histology at day 14 post-induction. Resolution, as 
determined by measurements of thrombus volume, vein lumen recanalisation 
and macrophage accumulation, was unchanged (P>0.05, Fig 3a-c). However, 
neovascular channel formation, at day 14 post-induction, was significantly 
enhanced by treatment with this inhibitor (P<0.05, Fig 3d). Treatment with 
JNJ-42041935 also resulted in a robust increase in haematocrit consistent 
with effective inhibition of PHD isoforms (P<0.01, Fig S1). 
Thrombus resolution in all-cell inducible Phd2 knockouts 
Thrombus resolution in all-cell inducible Phd2 knockouts was assessed 
longitudinally by 3D HFUS (Fig 4a). Thrombus volume in heterozygous and 
homozygous inducible Phd2 knockouts at days 1, 7 and 14 post-induction did 
not differ significantly from wild-type littermate controls (P>0.05 Fig 4b). To 
take into account differences in thrombus size at the time of formation rates of 
thrombus resolution were also determined. The rate of resolution between 
days 1-7 and 7-14 was similarly unaffected by deletion of phd2 (P>0.05, Fig 
4c). Vein lumen recanalisation, thrombus macrophage content and thrombus 
neovascularisation were unaltered in mice deficient for Phd2 when measured 
at day 14 post-induction (P>0.05, Fig 4d-f). Deletion of Phd2 was assessed in 
cytoplasmic preparations of kidney extracted at the time of thrombus 
collection. A significant reduction in the levels of PHD2 protein expression, but 
not PHD3, was observed in mice with a homozygous deficiency for Phd2 (Fig 
S2). Efficient deletion was further supported by significantly increased 
haematocrit measurements observed at day 14 post-induction in Phd2 
homozygous knockouts compared with wild-type littermate controls (P<0.001, 
Fig 4g). 
 
 
 
Discussion 
Thrombus resolution occurs through an organisational process of tissue 
remodelling, hallmarks of which include the recruitment of macrophages and 
the development of neovascular channels. We have previously suggested that 
the development of these channels is important for resolution 29 and may be 
enhanced by promoting HIF1α accumulation 5. PHD mediated regulation of 
HIF1α stability may, therefore, represent an important mechanism in the 
resolution of venous thrombi. This study investigates the effect of 
manipulating the expression and activity of PHD enzymes on thrombus 
resolution. 
 
Expression of all PHD isoforms was detected at both the transcriptional and 
protein level in the resolving thrombus. Temporal analysis of Phd gene 
expression revealed a significant increase in Phd2 gene expression as the 
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thrombus resolved. It is likely that these changes in expression can be 
attributed to the changing cellular composition of the thrombus as it resolves. 
PHD protein expression appears localised to inflammatory cells that 
accumulate within the thrombus. At acute time-points PHD protein expression 
was observed in polymorphonuclear cells, most likely neutrophils that 
predominate in the thrombus at this time 30. At later time-points PHD 
expression was observed in mononucleated cells, most likely macrophages 
recruited to the resolving thrombus 30, 31. It is, however, possible that at later 
time-points PHD isoforms are expressed in fibroblasts 32. 
 
Expression of PHD isoforms in both macrophages and neutrophils is 
consistent with recent observations. Neutrophils have been shown to express 
all three PHD isoforms with loss of Phd3 resulting in impaired survival of 
neutrophil under hypoxic challenge 33. PHD isoforms are considered important 
regulators of macrophage polarisation 34. Whereas loss of Phd2 results in 
skewing of macrophages towards an alternatively activated, pro-remodelling 
state 35 macrophages deficient in Phd3 demonstrate an enhanced pro-
inflammatory potential 36, 37.  
 
Given the observed expression of multiple PHD proteins in the resolving 
venous thrombus initial efforts focused on the effect of broad pharmacological 
PHD inhibition. The PHD inhibitors AKB-4924 15, a metal ion chelator and 
JNJ-42041935 16, a 2-oxoglutarate mimetic, were administered to mice and 
the effect on thrombus resolution determined. Treatment with either of these 
agents did not accelerate resolution, however, a significant (50%) increase in 
neovascular channel formation was observed at 14 days post-induction.  The 
pro-angiogenic effect of these agents is consistent with in vitro studies that 
demonstrate the capacity of AKB-4924 to stabilise HIFα subunits and induce 
expression of the transcriptional target Vegfa 38, 39. This observation is also 
supported by numerous in vitro studies in which classical PHD inhibtors were 
found to enhance angiogenesis, providing evidence for inhibitor activity in our 
model 40-42. Despite an established role for PHD isoforms in regulating 
macrophage function we did not observe a significant difference in recruitment 
of this cell type or evidence of differential remodelling of collagen (data not 
shown). 
 
Deletion of Phd2 confers an improved response to ischaemic challenge in a 
variety of cell types 19, 20, 35. An inducible strategy was selected because of the 
embryonic lethality of constitutive homozygous Phd2 deletion. Phd2 was 
deleted in all-cells in a tamoxifen dependent manner using the inducible 
Rosa26creERT2 line crossed onto the Phd2 floxed line. Tamoxifen was 
administered to mice for 5days immediately prior to induction of thrombus 
formation. It is important to note that a recent study has indicated that 
tamoxifen is an inhibitor of platelet activation and angiogenic potential and this 
may have altered thrombus resolution, however, all mice received tamoxifen 
and so this is likely controlled for in the experimental design 43. Deletion of 
Phd2 was confirmed by a significant reduction in renal PHD2 protein 
expression in inducible homozygous knockouts. This finding was further 
supported by significantly increased haematocrit observed in inducible 
homozygous Phd2 knockouts consistent with induction of the HIF target 
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erythropoietin 44. Elevated haematocrit has previously been reported in PHD 
deficient mice and supports effective deletion in this study 45, 46.  
 
The proportion of mice that formed thrombi did not differ significantly based on 
Phd2 genotype, however, a slight non-significant decrease in induction 
efficiency was noted in Phd2-/- mice compared to wild-type littermate controls 
(see supplementary Table 1). This study was not formally powered to 
determine the effect of Phd2 gene deletion on thrombus formation. It is 
interesting to consider whether hypoxic signalling may be involved in the 
pathogenesis in venous thrombus formation. Additional studies of Phd2 gene 
knockouts and pre-treatment with selective PHD inhibitors prior to thrombus 
induction may reveal a role for this family of enzymes in venous thrombus 
formation. 
 
Similar to studies of mice treated with PHD inhibitors, no significant 
differences in measures of thrombus resolution were observed in inducible 
Phd2 knockout mice. Unlike inhibitor treated mice, however, thrombus 
neovascularisation was largely unaffected by loss of Phd2 expression. As 
demonstrated by our gene expression and immunohistochemical staining both 
PHD1 and PHD3 are also expressed in the resolving thrombus. It is likely that 
in Phd2 knockouts expression of additional PHD isoforms compensate for 
loss of PHD2 activity. By contrast in studies using pan-PHD inhibitors all three 
isoforms are inhibited leading to a more pronounced upregulation of HIFα-
mediated angiogenic gene expression. Alternatively, it is possible that PHD1 
and PHD3 act as the primary regulators of angiogenic gene expression and 
subsequent thrombus resolution neovascularization. Future studies should 
investigate whether deletion of PHD1 or PHD3 is sufficient to promote 
thrombus neovascularization.  
 
It is possible that the observed increases in haematocrit after PHD inhibition 
or Phd2 gene deletion may have masked the expected pro-remodelling 
phenotype. Elevated haematocrit has been shown to increase platelet 
adhesion and thrombus formation under conditions of high shear 47. Recent 
work has further supported the prothrombotic potential of elevated 
haematocrit in a ferric chloride model of arterial thrombosis 48. Computational 
modelling further suggested that elevated haematocrit causes increased 
margination of platelets that may facilitate increased adhesion at sites of 
vascular injury 48. The contribution of changes in haematocrit to venous 
thrombus formation is, however, unclear. In our current study despite 
significantly elevated haematocrit we did not observe an increase in thrombus 
size at day 1 in inducible homozygous Phd2 knockouts suggesting a minimal 
contribution of haematocrit in this setting. 
 
The failure of AKB-4924 and JNJ-42041935 to accelerate venous thrombus 
resolution is in contrast to our previous observations with l-mimosine 6. As a 
potent ion chelator it is possible that l-mimosine inhibits targets, other than the 
PHD enzymes, that contribute to enhanced thrombus resolution 9-12. Further 
experiments are required to establish the mechanism of action by which l-
mimosine accelerates venous thrombus resolution. The results of the present 
study more closely agree with our experience overexpressing constitutively 
active HIF1α in the acute venous thrombus. Despite a significant increase in 
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levels of active HIF1α only a minor (20%), non-significant reduction in 
thrombus volume was observed at day 7 post-induction 7. Importantly, this 
genetic approach was not subject to the same potential for off-target effects 
as treatment with pharmacological inhibitors. Taken together with the current 
inhibitor studies these data would suggest that HIF1α plays a more limited 
role in thrombus resolution than previously hypothesised. 
 
During natural resolution the venous thrombus is permeated by a network of 
endothelial lined neovascular channels29. The contribution of thrombus 
neovascularisation to subsequent resolution, however, remains unclear, with 
conflicting data reported. Treatment with pro-angiogenic basic fibroblast 
growth factor significantly enhanced thrombus neovascularisation 
independent of changes in thrombus size in a rat model of IVC ligation49. 
Although treatment of thrombus with direct administration of an adenoviral 
VEGF-A gene construct resulted in a remarkable enhancement of thrombus 
resolution and vein recanalisation, this was mainly associated with 
macrophage infiltration rather than neovascular channel formation50. This 
study adds to the body of work suggesting that venous thrombus resolution is 
driven by processes other than neovascularisation that likely include 
macrophage-mediated tissue remodelling and fibrinolysis. The contribution of 
angiogenic factor signalling to thrombus resolution should not be discounted, 
however, as resolution is delayed in endothelial specific Vegfr2 knockouts 51.  
 
The results of this study lead us to conclude that broad-inhibition of PHD 
enzymes selectively enhances venous thrombus neovascularisation, but that 
this is largely independent of resolution. This suggests that direct targeting of 
angiogenesis alone may not be a viable therapeutic strategy for enhancing 
venous thrombus resolution. 
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Figures 
 
Figure 1: Expression of PHD isoforms in the naturally resolving venous 
thrombus  
PHD gene and protein expression was assessed in thrombi formed in 8-10 
week old male Balb/c mice. Gene expression of (a) Phd1, (b) Phd2, and (c) 
Phd3 was quantified by qPCR at days 1, 3, 7 and 11 post-induction (1-way 
ANOVA with post-hoc Bonferroni, n=5 per group) and expressed as 
normalised fluorescence intensity. (d) IHC localisation of PHD isoforms (black 
staining) expressing cells were localised to the naturally resolving venous 
thrombus at days 3 and 14 post-induction (n=4 per group). 
 
Figure 2: Effect of the PHD inhibitor AKB-4924 on venous thrombus 
resolution  
(a) Representative images of IVC resident thrombus visualised by contrast-
enhanced microCT at days 1, 7 and 14 post-induction after treatment with 
5mg/kg AKB-4924, 10mg/kg AKB-4924 or vehicle control (scale bar = 2mm). 
Contrast-enhanced microCT derived measurements of (b) thrombus volume 
or (c) rate of thrombus volume were unchanged by treatments (2-way and 1-
way ANOVA respectively P>0.05, n=6 per group). Endpoint histological 
measurements at 14days post induction of (d) thrombus volume, (e) vein 
lumen recanalisation and (f) macrophage recruitment were also unchanged 
(1-way ANOVA, P>0.05). (g) A significant increase in the number of CD31 
positive neovascular channels was observed after treatment with AKB-4924 
(1-way ANOVA P<0.001). Data represented as mean ± SE. *Post-hoc 
Bonferroni P<0.05 10mg/kg AKB-4924 vs vehicle. 
 
Figure 3: Effect of the PHD inhibitor JNJ-42041935 on venous thrombus 
resolution 
Histological measurements of (a) thrombus volume, (b) vein lumen 
recanalisation, (c) macrophage content and (d) thrombus neovascularisation 
at day 14 post-induction after treatment with 35mg/kg JNJ-42041935 were 
compared to vehicle control (students t-test, n= 9 per group). Data 
represented as mean ± SE. 
 
Figure 4: Effect of inducible Phd2 gene deletion on venous thrombus 
resolution 
(a) Representative transverse slices and 3D reconstructions of IVC resident 
thrombus (red dotted line) adjacent to the aorta (white arrowhead) visualised 
by 3D HFUS at days 1, 7 and 14 post-induction in wild-type, (scale bars = 
2mm). Measurements of (b) thrombus volume and (c) the rate of thrombus 
resolution derived from 3D HFUS were unchanged in Phd2fl/fl and Phd2fl/+ 
(Phd2+/+), Phd2fl/+;R26creERT2/+ (Phd2+/-) and Phd2fl/fl;R26creERT2/+ (Phd2-
/-) mice (2-way and 1-way ANOVA respectively, n=5-7 per group). End-point 
histological measurements, at 14 days post induction, of (d) vein lumen 
recanalisation, (e) macrophage content and (f) neovascularisation were also 
unchanged (1-way ANOVA). (g) End-point measurements of haematocrit 
were significantly increased in inducible homozygous Phd2 knockouts 
compared to wild-type littermate controls (1-way ANOVA). * Post-hoc 
Bonferroni P<0.05 -/- vs +/+. Data represented as mean ± SE. 
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Highlights 
- Tissue hypoxia is thought to be a critical driver of venous thrombus 
resolution 
- Prolyl hydroxylase domain proteins (PHDs) are critical oxygen sensors 
- Broad pharmacological PHD inhibition selectively enhances 
neovascularisation 
- Thrombus neovascularisation and resolution occur independent of 
Phd2 gene deletion 
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